Last reviewed · How we verify
Neoadjuvant olaparib (neoadjuvant-olaparib)
At a glance
| Generic name | neoadjuvant-olaparib |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Approved indications
Common side effects
- Anaemia
- Nausea
- Neutropenia
- Constipation
- Thrombocytopenia
- Leukopenia
- Decreased appetite
- Alopecia
- Fatigue
- Asthenia
- Diarrhoea
- Alanine aminotransferase increased
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neoadjuvant olaparib CI brief — competitive landscape report
- Neoadjuvant olaparib updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI